Acute Leukaemia

Measurability of Quality Performance Indicators Version 2.2

To be read in conjunction with:

- **Acute Leukaemia QPI Final Publication (Latest Published Version)**
- **Acute Leukaemia QPI Dataset (Latest Published Version)**

Measurability of Quality Performance Indicators for Acute Leukaemia

Document control:

This Version

Title	Acute Leukaemia Measurability of QPIs	**Version/Issue Number**	2.2
Effective From	July 2015	**Author**	Charlotte Anthony, ISD
Document Type	Guidance	**Document status**	Final
Document Purpose	Final Document for Publication		
Summary of changes	Including exact number of days for age groups		

Revision History

Version	Date	Status	Summary of Changes	QPI (s)
0.1	Oct 2013	Draft	First Draft	All
0.2	Mar 2014	Draft	Changes following Public Engagement	All
0.3	Mar 2014	Draft	Changes following Public Engagement	All
0.4	April2014	Draft	Comments from IS (mainly changing definition of curative/palliative care to Intent)	All
0.5	May 2014	Draft	Minor changes following board review	3.5,7,8
1.0	July 2014	Final	Final Document for Publication	All
2.0	April 2015	Final	Changes made following 9 month review	2, 5,12
2.1	Dec 2015	Final	Changes made outwith review	5
2.2	Aug 2016	Final	Changes made following Baseline Review	2, 5, 6, 7, 9, 10, 12

Updates from Previous Version

QPI	Summary of changes (excluding formatting changes) (August 2016)
2	Denominator amended from '[MODE1 <> 14]' to '[MODE1 <> 14] AND [MODE2 <> 14] AND [MODE3 <> 14] AND [MODE4 <> 14]'
5	Numerator (i) and (ii): replace 'proportion' with 'number'. Denominator (i), Patients between 16 years of age and 60 years of age and Patients over 60 years of age: add 'OR 04A OR 04B]' to MODE1. Denominator (ii): add '*OR Biological Therapy OR Biological Therapy – All Trans-Retinoic Acid (ATRA)'; add '*OR 04A OR 04B]' to MODE1 in Patients under 16 years of age, Patients between 16 years of age and 60 years of age and Patients over 60 years of age.
6	QPI Title, Description and Numerator: replace '24hours' with 'one day'.
7	Add note: '**Please Note:** This QPI will be reported 1 year in arrears to ensure accurate and appropriate reporting against this QPI'
9	Numerator: replace 'proportion' with 'number'
10	Denominator (ii): add exclusion '*Excluding patients who refuse entry into a clinical trial'* Not recorded for exclusion: add '(ii) [TRIAL = 99]'
12	Denominator calculation: add '9895/3'; delete '9861/3'

QPI	Summary of changes (excluding formatting changes) (December 2015)
5	(Query 1115) Denominator amend –"Type of Treatment 1 coded as Chemotherapy – Intensive, [MODE1 = 01A]" to "Type of Treatment 1 coded as Chemotherapy – Intensive OR Biological Therapy OR Biological Therapy – All Trans-Retinoic Acid (ATRA), [MODE1 = 01A OR 04A OR 04B]

QPI	Summary of changes (excluding formatting changes) (April 2015)
2	NR numerator removed FINALDIAG = 9999/9 and inserted N/A (patients not recorded for the numerator are included in the 'numerator not met' category for this standard)
5	Removed OR9898/3 from Denominator (i); Amended numerator (ii) from < to ≤ 35 days
12	Removed OR9898/3 from Denominator

QPI 1 – Complete Diagnostic Panel

QPI Title:	Patients with acute leukaemia should have complete diagnostic panel undertaken to inform appropriate management.
Description:	Proportion of patients with acute leukaemia undergoing treatment with curative intent who have complete diagnostic panel undertaken, this includes: (i) Morphology; (ii) Immunophenotyping; (iii) Cytogenetics; and (iv) Storage of genetic material for routine diagnostic testing.
Numerator	Number of patients with acute leukaemia undergoing treatment with curative intent where complete diagnostic panel undertaken. Final Diagnosis not coded as Not Recorded; Immunophenotyping Performed coded as Yes or Failed; and Cytogenetic Analysis Performed coded as Yes or Failed; and Molecular Marker Analysis Performed coded as Yes or Failed; and Genetic Material Stored coded as Yes. [FINALDIAG <> 9999/9] **AND** [IMMUNOTYPE = 01 OR 98] **AND** [CYTOANALYSIS = 01 OR 98] **AND** [GENMATSTOR = 01]
Denominator	All patients with acute leukaemia undergoing treatment with curative intent. (No exclusions). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Intent coded as Curative. [INTENT = 01]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [FINALDIAG = 9999/9] **OR** [IMMUNOTYPE = 99] **OR** [CYTOANALYSIS = 99] **OR** [GENMATSTOR = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [INTENT = 99] OR [DIAGDATE = 09/09/0909]

QPI 2 – Diagnostic Classification

QPI Title:	Patients with acute leukaemia should have a World Health Organisation Classification recorded to facilitate appropriate management.
Description:	Proportion of patients with acute leukaemia who have World Health Organisation (WHO) classification assigned and recorded (either by multi-disciplinary team (MDT) or reporting haematologist/haematopathologist).
Numerator	Number of patients with acute leukaemia who have WHO classification assigned and recorded (either by MDT or reporting haematologist/ haematopathologist). Final Diagnosis not coded as Not Recorded. [FINALDIAG <> 9999/9]
Denominator	All patients with acute leukaemia. (Excluding patients receiving supportive care / palliation only). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Type of Treatment 1-4 not coded as Supportive Care. [MODE1 <> 14] AND [MODE2 <> 14] AND [MODE3 <> 14] AND [MODE4 <> 14]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target N/A ***(patients not recorded for the numerator are included in the 'numerator not met' category for this standard)***
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [MODE1 = 99]
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [DIAGDATE = 09/09/0909]

QPI 3 - MDT Discussion

QPI Title:	Patients with acute leukaemia should be discussed by a multidisciplinary team (MDT) at diagnosis.
Description:	Proportion of patients with acute leukaemia who are discussed at MDT meeting within 6 weeks of diagnosis.
Numerator	Number of patients with acute leukaemia discussed at MDT meeting within 6 weeks of diagnosis. Date Discussed by Care Team (MDT) not coded as Inapplicable; and Date Discussed by Care Team (MDT) minus Date of First Diagnosis {Acute Leukaemia} less than 6 weeks [MDTDATE <> 10/10/1010] **AND** [MDTDATE – DIAGDATE ≤ 42 days]
Denominator	All patients with acute leukaemia. Date of Diagnosis [DIAGDATE] in range specified for comparative analysis
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MDTDATE = 09/09/0909]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [DIAGDATE = 09/09/0909]

QPI 4 – Minimal Residual Disease Marker

QPI Title:	Patients with Acute Lymphoblastic Leukaemia (ALL) under the age of 25 receiving curative treatment should be assessed for the presence of Minimal Residual Disease (MRD) marker.
Description:	Proportion of patients with ALL, <25 years of age, undergoing treatment with curative intent who are assessed for the presence of MRD marker.
Numerator	Number of patients with ALL, <25 years of age, undergoing treatment with curative intent who are assessed for the presence of MRD marker. Assessment for Minimal Residual Disease Marker (at Diagnosis) coded as Yes. [MRDMARK = 01]
Denominator	All patients with ALL, <25 years of age, undergoing treatment with curative intent. (No exclusions). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis**;** Final Diagnosis coded as Acute Lymphoblastic Leukaemia (ALL); Date of Diagnosis minus Date of Birth less than 25 years; and Intent coded Curative. [FINALDIAG = 9811/3 OR 9812/3 OR 9813/3 OR 9814/3 OR 9815/3 OR 9816/3 OR 9817/3 OR 9818/3 OR 9837/3] **AND** [DIAGDATE – DOB < 25 years [<9131 days]] **AND** [INTENT = 01]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MRDMARK = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [FINALDIAG = 9999/9] **OR** [DIAGDATE = 09/09/0909] **OR** [INTENT = 99]

QPI 5 – Early Deaths

QPI Title:	Mortality rate following diagnosis of acute leukaemia.
Description:	Proportion of patients with acute leukaemia being treated with curative intent who die within 30/35 days of treatment. **Please note:** This QPI measures 2 distinct elements: i. Patients with Acute Myeloid Leukaemia (AML) treated with curative intent who die within 30 days of treatment; and ii. Patients with Acute Lymphoblastic Leukaemia (ALL) treated with curative intent who die within 35 days of treatment.
Numerator (i)	Number of patients with AML being treated with curative intent who die within 30 days of treatment Date Treatment Completed 1 not coded as Inapplicable and less than or equal to 30 days before Date of Death. [TREATENDATE1 <> 10/10/1010] **AND** [DOD – TREATENDATE1 ≤ 30 days]
Denominator (i)	All patients with AML being treated with curative intent. (No exclusions). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Final Diagnosis coded as acute Myeloid Leukaemia (AML]; and Intent coded as Curative; and Type of Treatment 1 coded as Chemotherapy – Intensive OR Biological Therapy OR Biological Therapy – All Trans-Retinoic Acid (ATRA); and Date of Diagnosis minus Date of Birth less than 16 years / between 16 and 60 / over 60 years. <u>Patients under 16 years of age</u> [FINALDIAG = 9896/3 OR 9871/3 OR 9866/3 OR 9897/3 OR 9865/3 OR 9869/3 OR 9911/3 OR 9861/3 OR 9895/3 OR 9920/3 OR 9872/3 OR 9873/3 OR 9874/3 OR 9867/3 OR 9891/3 OR 9840/3 OR 9910/3 OR 9870/3 OR 9931/3 OR 9861/3 OR 9930/3 OR 9801/3 OR 9806/3 OR 9807/3 OR 9808/3 OR 9809/3] **AND** [INTENT = 01] **AND** [MODE1 = 01A OR 04A OR 04B] **AND** [DIAGDATE – DOB < 16years [<5844 days]] <u>Patients between 16 years of age and 60 years of age</u> [FINALDIAG = 9896/3 OR 9871/3 OR 9866/3 OR 9897/3 OR 9865/3 OR 9869/3 OR 9911/3 OR 9861/3 OR 9895/3 OR 9920/3 OR 9872/3 OR 9873/3 OR 9874/3 OR 9867/3 OR 9891/3 OR 9840/3 OR 9910/3 OR 9870/3 OR 9931/3 OR 9861/3 OR 9930/3 OR 9801/3 OR 9806/3 OR 9807/3 OR 9808/3 OR 9809/3] **AND** [INTENT = 01] **AND** [MODE1 = 01A OR 04A OR 04B]] **AND** [DIAGDATE – DOB ≥ 16years [≥5844 days] and ≤60years [≤21915 days]] <u>Patients over 60 years of age</u> [FINALDIAG = 9896/3 OR 9871/3 OR 9866/3 OR 9897/3 OR 9865/3 OR 9869/3 OR 9911/3 OR 9861/3 OR 9895/3 OR 9920/3 OR 9872/3 OR 9873/3 OR 9874/3 OR 9867/3 OR 9891/3 OR 9840/3 OR 9910/3 OR 9870/3 OR 9931/3 OR 9861/3 OR 9930/3 OR 9801/3 OR 9806/3 OR 9807/3 OR 9808/3 OR 9809/3] **AND** [INTENT = 01] **AND** [MODE1 = 01A OR 04A OR 04B] **AND**

	[DIAGDATE – DOB > 60years [>21915 days]]
Numerator (ii)	Number of patients with ALL being treated with curative intent who die within 35 days of treatment. Date Treatment Completed 1 not coded as Inapplicable and less than 35 days before Date of Death. [TREATENDATE1 <> 10/10/1010] AND [DOD – TREATENDATE1 ≤ 35 days]
Denominator (ii)	All patients with ALL being treated with curative intent. *(No exclusions).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Final Diagnosis coded as Acute Lymphoblastic Leukaemia (ALL)**;** and Intent coded as Curative; and Type of Treatment 1 coded as Chemotherapy – Intensive OR Biological Therapy OR Biological Therapy – All Trans-Retinoic Acid (ATRA); and Date of First Diagnosis minus Date of Birth less than 16 years / over 16 years / over 60 years. <u>Patients under 16 years of age</u> [FINALDIAG = 9811/3 OR 9812/3 OR 9813/3 OR 9814/3 OR 9815/3 OR 9816/3 OR 9817/3 OR 9818/3 OR 9837/3] **AND** [INTENT = 01] **AND** [MODE1 = 01A OR 04A OR 04B] **AND** [DIAGDATE – DOB < 16years [<5844 days]] <u>Patients between 16 years of age and 60 years of age</u> [FINALDIAG = 9811/3 OR 9812/3 OR 9813/3 OR 9814/3 OR 9815/3 OR 9816/3 OR 9817/3 OR 9818/3 OR 9837/3] **AND** [INTENT = 01] **AND** [MODE1 = 01A OR 04A OR 04B] **AND** [DIAGDATE – DOB ≥ 16years [≥5844 days] and ≤60years [≤21915 days]] <u>Patients over 60 years of age</u> [FINALDIAG = 9811/3 OR 9812/3 OR 9813/3 OR 9814/3 OR 9815/3 OR 9816/3 OR 9817/3 OR 9818/3 OR 9837/3] **AND** [INTENT = 01] **AND** [MODE1 = 01A OR 04A OR 04B] **AND** [DIAGDATE – DOB > 60years [>21915 days]]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [[TREATENDATE1 = 09/09/0909] OR [DOD = 09/09/0909]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [FINALDIAG = 9999/9] **OR** [INTENT = 99] **OR** [MODE1 = 99] **OR** [DIAGDATE = 09/09/0909]

QPI 6 – Access to ATRA for Patients with Acute Promyelocytic Leukaemia

QPI Title:	Patients with suspected Acute Promyelocytic Leukaemia (APL)* should undergo treatment with All Trans-Retinoic Acid (ATRA) within 1 day of diagnosis.
Description:	Proportion of patients with APL who receive ATRA within 1 day of diagnosis.
Numerator	Number of patients with APL who receive ATRA within 1 day of diagnosis. Type of Treatment1-4 coded as ATRA; and Date Treatment Started 1-4 minus Date of Final Diagnosis less than or equal to 1 day. [MODE1 = 04B] **AND** [TREATDATE1 –DIAGDATE ≤ 1 DAY]
Denominator	All patients with APL.(No exclusions). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Final Diagnosis coded as Acute Promyelocytic Leukaemia [FINALDIAG = 9866/3]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [TREATDATE1 = 09/09/0909] **OR** [MODE1 = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [FINALDIAG = 9999/9] OR [DIAGDATE = 09/09/0909]

QPI 7 – Deaths in Remission

QPI Title:	Remission deaths for patients with acute leukaemia receiving treatment with curative intent.
Description:	Proportion of patients with acute leukaemia undergoing treatment with curative intent who die in first complete remission (CR)[a], within 1 year of diagnosis.
Numerator	Number of patients with acute leukaemia undergoing treatment with curative intent who achieve first CR and die within 1 year of diagnosis, whilst in CR. Date of Death minus Date of Diagnosis ≤ 1year; and First Complete Remission Maintained at Time of Death coded as Yes; and Date of Death not coded as Not Applicable. [DOD – DIAGDATE ≤ 1year [365 days]] AND [DEATHRS = 01] AND [DOD <> 10/10/1010]
Denominator	All patients with acute leukaemia undergoing treatment with curative intent who achieve first CR. *(Excluding patients undergoing bone marrow / stem cell transplant).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Intent coded as curative; and Remission Status coded as Complete Remission (CR) or Complete Remission with incomplete recovery (CRi); and Type of Treatment 1-4 not coded as Transplant - Autologous or Transplant – Allogenic; and Date of Diagnosis minus Date of Birth less than 16 years / over 16 years. <u>Patients under 16 years of age</u> [INTENT = 01] **AND** [REMISSTAT = 01 OR 02] **AND** [MODE1 OR MODE2 OR MODE3 OR MODE4 <> 07A OR 07B] **AND** [DIAGDATE – DOB < 16years [<5844 days]] <u>Patients aged 16 years and over</u> [INTENT = 01] **AND** [REMISSTAT = 01 OR 2] **AND** [MODE1 OR MODE2 OR MODE3 OR MODE4 <> 07A OR 07B] **AND** [DIAGDATE – DOB ≥ 16years [≥5844 days]]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [DEATHRS = 99] OR [DOD = 09/09/0909]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.

[a] Within the measurement of this QPI complete remission as confirmed by morphology will be utilised.

	[MODE1 OR MODE2 OR MODE3 OR MODE4 = 99]
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [INTENT = 99] **OR** [REMISSTAT = 99] **OR** [DIAGDATE = 09/09/0909]

Please Note: This QPI will be reported 1 year in arrears to ensure accurate and appropriate reporting against this QPI.

QPI 8 – Clinical Trials with Curative Intent

QPI Title:	Patients with acute leukaemia under 60 years of age[c] who are suitable for treatment with curative intent should be considered for participation in available clinical trials, wherever eligible.
Description:	Proportion of patients with acute leukaemia being treated with curative intent who are enrolled in a clinical trial.
Numerator	Number of patients with acute leukaemia who are treated with curative intent enrolled in a clinical trial. Patient Entered into Clinical Trial coded as Yes [TRIAL = 01]
Denominator	All patients with acute leukaemia who are treated with curative intent. (Excluding patients who refuse entry into a clinical trial and patients over 60 years of age). [b]. Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Intent coded as Curative; and Patient Entered into Clinical Trial Not coded as Refused Entry; and Date of Diagnosis minus Date of Birth less than 16 years / between 16 and 60 years. <u>Patients under 16 years of age</u> [INTENT = 01] **AND** [TRIAL <> 95] **AND** [DIAGDATE – DOB < 16years [<5844 days]] <u>Patients aged between 16 and 60 years of age</u> [INTENT = 01] **AND** [TRIAL <> 95] **AND** [DIAGDATE – DOB ≥ 16years [≥ 5844] and ≤60years [≤21915 days]]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [TRIAL = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [TRIAL = 99]

[b] Patients over 60 years of age are specifically included in QPI 10

Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [INTENT = 99] **OR** [DIAGDATE = 09/09/0909]

QPI 9 – Tissue Typing for Transplant

QPI Title:	Patients with acute leukaemia treated with curative intent should have a specimen sent to the lab for tissue typing at diagnosis.
Description:	Proportion of patients with acute leukaemia eligible for transplant (i.e. over 16 years of age and under 65 years of age) being treated with curative intent should have a specimen sent to the lab for tissue typing at diagnosis.
Numerator	Number of patients with acute leukaemia between 16 and 65 treated with curative intent with a specimen sent to the lab for tissue typing at diagnosis. Tissue Typing Sample Taken (at Diagnosis) coded as Yes [TTSAMP = 01]
Denominator	All patients with acute leukaemia between 16 and 65 being treated with curative intent. *(No exclusions).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Date of Diagnosis minus Date of Birth >= 16 and <= 65 years; and Intent coded as curative. [DIAGDATE – DOB ≥16 [≥5844 days] AND ≤65 [≤23741 days]] **AND** [INTENT = 01]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [TTSAMP = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [DIAGDATE = 09/09/0909] **OR** [INTENT = 99].

QPI 10 – Intensive Chemotherapy in Older Adults

QPI Title:	Patients with acute leukaemia over 60 years of age should be offered intensive chemotherapy, within the context of a clinical trial wherever possible, as this provides quality of life and survival benefit.
Description:	Proportion of patients with acute leukaemia over 60 years of age with performance status (PS) 0-1 who receive intensive chemotherapy. **Please note:** This QPI measures 2 distinct elements: i. Patients with acute leukaemia over 60 years of age who receive intensive chemotherapy; and ii. Patients with acute leukaemia over 60 years of age receiving intensive chemotherapy who are treated within a clinical trial.
Numerator (i)	Number of patients with acute leukaemia aged 60 years of age and over with PS 0-1 who receive intensive chemotherapy. Type of Treatment 1-4 coded as Intensive chemotherapy [MODE1 OR MODE2 OR MODE3 OR MODE4 = 01A]
Denominator (i)	All patients with acute leukaemia aged 60 years of age and over with PS 0-1. (No exclusions). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Date of Diagnosis minus Date of Birth >60 years; and WHO/ ECOG Performance Status coded as Fully active, able to carry on all pre-disease performance without restriction or Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light housework, office work [DIAGDATE – DOB ≥60 [≥21915 days]] **AND** [PSTATUS = 0 OR 1]
Numerator (ii)	Number of patients with acute leukaemia aged 60 years of age and over who receive intensive chemotherapy enrolled in a clinical trial. Patient entered into Clinical Trial coded as Yes [TRIAL = 01]
Denominator (ii)	All patients with acute leukaemia aged 60 years of age and over who receive intensive chemotherapy. *(Excluding patients who refuse entry into a clinical trial).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Date of Diagnosis minus Date of Birth >60 years; and Type of Treatment 1-4 coded as Intensive chemotherapy; and Patient Entered into Clinical Trial Not coded as Refused Entry [DIAGDATE – DOB ≥60 [≥21915 days]] **AND** [MODE1 OR MODE2 OR MODE3 OR MODE4 = 01A] AND [TRIAL <> 95]

Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target (i) [MODE1 OR MODE2 OR MODE3 OR MODE4 = 99] (ii) [TRIAL = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. (ii) [TRIAL = 99]
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard (i) [DIAGDATE = 09/09/0909] **OR** [PSTATUS = 99] (ii) [DIAGDATE = 09/09/0909] **OR** [MODE1 OR MODE2 OR MODE3 OR MODE4 = 99]

QPI 11 – Clinical Trials with Non Curative Intent

QPI Title:	Patients with acute leukaemia who are suitable only for treatment with non-curative intent should be considered for participation in available clinical trials, wherever eligible.
Description:	Proportion of patients with acute leukaemia being treated with non curative intent who are enrolled in a clinical trial.
Numerator	Number of patients with acute leukaemia who are treated with non-curative intent enrolled in a clinical trial. Patient entered into Clinical Trial coded as Yes [TRIAL = 01]
Denominator	All patients with acute leukaemia who are treated with non-curative intent. (Patients who refuse entry into a clinical trial). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Intent coded as Non-Curative; and Patient entered into Clinical Trial not coded as Patient Refused. **(** [INTENT = 02] **AND** [TRIAL <> 95]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [TRIAL = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [TRIAL = 99]
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [INTENT = 99] OR [DIAGDATE = 09/09/0909]

QPI 12 - Palliative Treatment

QPI Title:	Patients with acute myeloid leukaemia (AML) who are suitable only for treatment with non-curative intent should receive treatment with an appropriate palliative chemotherapy regimen.
Description:	Proportion of patients with AML who are suitable only for treatment with non-curative intent who receive an appropriate palliative chemotherapy regimen[c].
Numerator	Number of patients with acute myeloid leukaemia who are suitable only for treatment with non-curative intent who receive palliative chemotherapy with either low dose cytarabine or azacytidine. Type of Treatment 1-4 coded as Low Dose Chemotherapy. [MODE1 OR MODE2 OR MODE3 OR MODE4 = 01B]
Denominator	All patients with acute myeloid leukaemia who are suitable only for treatment with non-curative intent. (Excluding patients who refuse chemotherapy treatment and patients with adverse cytogenetics). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Final Diagnosis coded as acute Myeloid Leukaemia (AML]; and Intent coded as Non Curative and Type of Treatment 1-4 not coded as Patient Refused; and Cytogenetics/Molecular Risk Group not coded as Adverse. [FINALDIAG = 9896/3 OR 9871/3 OR 9866/3 OR 9897/3 OR 9865/3 OR 9869/3 OR 9911/3 OR 9861/3 OR 9895/3 OR 9920/3 OR 9872/3 OR 9873/3 OR 9874/3 OR 9867/3 OR 9891/3 OR 9840/3 OR 9910/3 OR 9870/3 OR 9931/3 OR 9930/3 OR 9801/3 OR 9806/3 OR 9807/3 OR 9808/3 OR 9809/3] **AND** [INTENT = 02] [MODE1 OR MODE2 OR MODE3 OR MODE4 <> 95] **AND** [ADVERCYTO <> 03]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MODE1 OR MODE2 OR MODE3 OR MODE4 = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [MODE1 OR MODE2 OR MODE3 OR MODE4 = 99] **OR** [ADVERCYTO = 99]
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [FINALDIAG = 9999/9] **OR [**INTENT= 99**] OR [**DIAGDATE = 09/09/0909**]**

[c] Appropriate chemotherapy regimen will include any chemotherapy drug which is licensed in this indication, for example cytarabine or azacitidine.